Actinium's Market for Targeted Conditioning with their revolutionary AWE platform

NEW YORK - Aug. 11, 2020 - PRLog -- Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology. The technology enables the development of breakthrough Antibody Radiation-Conjugates (ARCs), that combine the targeting ability of antibodies with the cell killing ability of radiation.

Key Triggers

SIERRA TRIAL (Acute Myeloid Leukemia) enabling Apamistamab Iomab-B for serving 128,000 BMT patients by 2028, once approved, Ad hoc analysis expected in Q4:2020

Possibilities of AWE Platform- Delivers radiation directly to target cells

Myeloablative Conditioning in case of Bone Marrow Transplantation

Reduced Intensity Conditioning to deliver targeted conditioning agent with stem cell gene therapy for patients with HIV-related lymphoma

Safer and targeted lymphodepletion to expand patient access to Adoptive Cell Therapy (CAR-Ts)

Expanded programs involving Actimab-A in combination with chemotherapy, targeted agents and immunotherapy and Next-generation Empowered Antibodies via AWE Platform

Key Partnerships for research and development for AWE platform

Things to know

• The leading product, Apamistamab Iomab-B (131-I-labeled anti-CD45 antibody) is THE ATTRACTIVE product in the clinical pipeline with the consistent predictive trends at halfway point in SIERRA Trial for the R/R AML patients (aged above 55 years) undergoing BMT

• 100% engraftment in AML patients at day 28
• Provided 6X difference in efficacy (durable complete remission) vs BEAM chemotherapy conditioning at 50% enrollment
• Need to show a 2x difference in dCR primary endpoint at full enrollment [Final goal]
• The overall survival rate of the 36 relapsed or refractory AML patients in the proof of concept study was 30% at one year and approximately 20% at two years
• Reduce time, burden and toxicities associated with conditioning

• No competition [Well, supporting their indirect competitors with their attractive and un-resistible platform]

Actinium Pharmaceuticals' Actinium's Antibody Warhead Enabling (AWE) platform
CD45- Iomab-B BMT

Actinium's lead CD45 targeted conditioning product candidate, Iomab-B uses high doses of I-131 to achieve myeloablative conditioning prior to a BMT. Iomab-B is currently being studied in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory acute myeloid leukemia (AML), or SIERRA, clinical trial for targeted conditioning.

Dr Richard T. Maziarz, MD, Oregon Health & Science University said,

"This could be a viable option and a change of practice for a patient population suffering with refractory leukemia who has failed multiple chemotherapy regimens and other interventions, for whom we have nothing else to offer"

Key takeaways from Actinium's impressive pipeline- Mellalta Meets findings

https://mellalta.com/actiniums-multi-billion-dollar-market-for-targeted-conditioning-with-their-revolutionary-antibody-warhead-enabling-awe-platform/

Submit your Request for Proposals at bd@mellalta.com